Antiandrogens
Aspirin
Bamlanivimab
Bromhexine
Budesonide
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Povidone-Iod..
Probiotics
Proxalutamide
Quercetin
Remdesivir
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc

Other
Feedback
Home
Top
3-O-β-D-glucos..
7-hydroxystaur..
76clAbs
abacavir
acarbose
adamumab
adefovir
Aframomum mele..
Afzelin
agomelatine
amantadine
amiodarone
amitriptyline
amlodipine
amodiaquine
amprenavir
Amygdalin
anakinra
Andrographolide
Anhydrosafflor..
Anisodamine
apalutamide
Apigenin
apixaban
APN01
aprotinin
arbidol
ARD-61
Arq Ajīb
Artemisia annua
ASC09
Ashwagandha
Astragaloside IV
atazanavir
atorvastatin
atovaquone
Atractylenolid..
avdoralimab
AZD7442
Azelastine
azithromycin
azvudine
bafetinib
baicalein
Baicalin
baloxavir marb..
baricitinib
beauvericin
bedaquiline
Benzoic acid
bevacizumab
Bicuculline
Biorobin
Bis-demethoxyc..
brazilin
BRII-196/BRII-..
bromelain
C60 fullerene
Caffeic acid
calpeptin
camostat
cannabidiol
carrimycin
carvedilol
Catechin
Cepharanthine
cetirizine
cetylpyridiniu..
CF101
chlorhexidine
Chlorogenic acid
Chrysin
Chyawanprash
ciclesonide
Citronellol
clazakizumab
clevudine
clofoctol
CLSP-2
cobicistat
Codivir
copper(II) glu..
Cryptoquindoline
Cryptospirolep..
Cryptotanshinone
CT-P59
CTB-ACE2 gum
Cucurbitacin G..
cyanidin
CYNK-001
cysteamine HCl
Daidzein
danoprevir
darolutamide
darunavir
Darunavir Etha..
Daturaolone
delavirdine
Delphinidin
Demethylzeylas..
desloratadine
dexchlorphenir..
diammonium gly..
didanosine
Dieckol
dihydroartemis..
Dimethyl Sulfo..
Diosbulbinosid..
diphenhydramine
disulfiram
dithymoquinone
dolutegravir
doramectin
doxazosin
doxycycline
ebastine
eculizumab
Ellagic acid
Emodin
emtricitabine
enalapril
engineered ACE2
enoxaparin
enzalutamide
Ephedrine
epicatechin
epigallocatechin
estradiol
estragole
Estrone-2,3-qu..
etanercept
ethoxzolamide
ethyl lauroyl ..
Euchrenone
eugenol
Evusheld
EXO-CD24
ezetimibe
famotodine
Fangchinoline
Farnesiferol B
fenofibrate
Ferrocene deri..
Ferulic acid
fingolimod
flecainide
FLOVID-20
fluoxetine
Forsythoside A
Forsythoside I
Fostamatinib
fucoidan
Galangin
galidesivir
Gallic acid
ganciclovir
Genistein
gimsilumab
Glabridin
glutathione
glycyrrhiza gl..
Green Tea
Griffithsin
heparin
Hesperidin
honey
Huashibaidu
hydrogen perox..
hydroxyzine
Hypericin
ibrutinib
ibuprofen
IFN-β1a
IFN-β1b
IFX-1
imatinib
immunoglobulin
indinavir
Indomethacin
infliximab
interleukin-2
Irisolidone
Isatis indigot..
Isoferulic acid
Isorhamnetin
jakotinib hydr..
Jing Si
Jinhua Qinggan
JS016
Kabasura Kudin..
Kaempferol
Kobophenol A
L-arginine
L-Lysine
lactoferrin
leflunomide
lenzilumab
leronlimab
levilimab
Lianhua Qingwen
Limonene
Limonin
lopinavir
loratadine
losartan
Lung Cleansing..
Luteolin
LY2835219
LY3127804
manidipine
Manuka honey
masitinib
Maslinic acid
Mearnsitrin
meplazumab
MesenCure
methylene blue
Methylephedrine
MUC1
multimeric sol..
myricetin
Myricitrin
N-Acetylcysteine
N-acetylglucos..
nafamostat
naproxen
Naringenin
natto extract
neem
negillicine
nelfinavir
Neochlorogenic..
niacinamide
niclosamide
nicotinamide m..
nicotine
nitric oxide
nivolumab
Obacunone
obtivo
Oleuropein
Omega 3
Oroxylin A
oxygen-ozone i..
p-coumaroyltri..
palmitoylated ..
panobinostat
paritaprevir
paroxetine
pegylated inte..
pentosan polys..
Phillyrin
phosphodiester..
phthalocyanine
piclidenoson
piperaquine
pirfenidone
Poly-hydroxyfl..
Poly-methoxyfl..
Pomegranate
probenecid
Procyanidin
propolis
propolis sulab..
Pseudoephedrine
Psoralidin
Pterostilbene
Puerarin
Pyramax
pyronaridine
Q34
Quercetin 3-O-..
raltegravir
ramelteon
ramipril
ravulizumab
RD-X19
regdanvimab
resveratrol
Rhein
Rheum palmatum
Rhizoma Cibotii
ribavirin
ritonavir
rosuvastatin
rutin
ruxolitinib
saline
Salvianolic acid
saquinavir
Scutellarein
sea cucumber s..
selamectin
selenium
sertraline
Sesamin
Sesaminol
Sesamolin
Shuang Huang L..
silibinin
Silmitasertib
SN00074072
sodium bicarbo..
sofosbuvir
Solanine
Speciophylline
spironolactone
Spirulina
stenoparib
suramin sodium
tannic acid
Tanshinones
Taraxerol
telmisartan
tenofovir alaf..
tenofovir diso..
Tetrandrine
theaflavin-3,3..
thiamine
thymic peptides
TJ003234
tocilizumab
tofacitinib
Tollovir
toremifene
Torreya nucifera
tozumab
TriSb92
ubiquinone
Uncaric acid
Uncarine F
Urso-deoxychol..
Ursolic acid
valsartan
Withanolide A
Xanthoangelol E
Xuanfeibaidu
Xuebijing
xylitol
ZINC02111387
ZINC02122196
ZINC04090608
α-hederin
α-lactalbumin
β-glucan
β-sitosterol
δ-viniferin

Feedback
Home   COVID-19 treatment studies  COVID-19 treatment studies  COVID-19 studies   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Metformin (meta)
Aspirin (meta) Molnupiravir (meta)
Bamlanivimab (meta) Nigella Sativa (meta)
Bromhexine (meta) Nitazoxanide (meta)
Budesonide (meta) Paxlovid (meta)
Casirivimab/i.. (meta) Povidone-Iod.. (meta)
Colchicine (meta) Probiotics (meta)
Conv. Plasma (meta) Proxalutamide (meta)
Curcumin (meta) Quercetin (meta)
Favipiravir (meta) Remdesivir (meta)
Fluvoxamine (meta) Sotrovimab (meta)
Hydroxychlor.. (meta) Vitamin A (meta)
Iota-carragee.. (meta) Vitamin C (meta)
Ivermectin (meta) Vitamin D (meta)
Melatonin (meta) Zinc (meta)
Other Treatments Global Adoption
Early treatments for COVID-19
Home   
Share  
Tweet
  Global AdoptionAdoption
  Submit FeedbackFeedback
350 other treatments reported as potentially beneficial for early treatment of COVID-19 in studies. We have not reviewed these studies.
Submit Corrections or Updates
3-O-β-D-glucoside   7-hydroxystaurosporine   76clAbs   abacavir   acarbose   adamumab   adefovir   Aframomum melegueta   Afzelin   agomelatine   amantadine   amiodarone   amitriptyline   amlodipine   amodiaquine   amprenavir   Amygdalin   anakinra   Andrographolide   Anhydrosafflor yellow B   Anisodamine   apalutamide   Apigenin   apixaban   APN01   aprotinin   arbidol   ARD-61   Arq Ajīb   Artemisia annua   ASC09   Ashwagandha   Astragaloside IV   atazanavir   atorvastatin   atovaquone   Atractylenolide III   avdoralimab   AZD7442   Azelastine   azithromycin   azvudine   bafetinib   baicalein   Baicalin   baloxavir marboxil   baricitinib   beauvericin   bedaquiline   Benzoic acid   bevacizumab   Bicuculline   Biorobin   Bis-demethoxycurcumin   brazilin   BRII-196/BRII-198   bromelain   C60 fullerene   Caffeic acid   calpeptin   camostat   cannabidiol   carrimycin   carvedilol   Catechin   Cepharanthine   cetirizine   cetylpyridinium chloride   CF101   chlorhexidine   Chlorogenic acid   Chrysin   Chyawanprash   ciclesonide   Citronellol   clazakizumab   clevudine   clofoctol   CLSP-2   cobicistat   Codivir   copper(II) gluconate   Cryptoquindoline   Cryptospirolepine   Cryptotanshinone   CT-P59   CTB-ACE2 gum   Cucurbitacin G 2-glucoside   cyanidin   CYNK-001   cysteamine HCl   Daidzein   danoprevir   darolutamide   darunavir   Darunavir Ethanolate   Daturaolone   delavirdine   Delphinidin   Demethylzeylasteral   desloratadine   dexchlorpheniramine   diammonium glycyrrhizinate   didanosine   Dieckol   dihydroartemisinine   Dimethyl Sulfoxide   Diosbulbinoside D   diphenhydramine   disulfiram   dithymoquinone   dolutegravir   doramectin   doxazosin   doxycycline   ebastine   eculizumab   Ellagic acid   Emodin   emtricitabine   enalapril   engineered ACE2   enoxaparin   enzalutamide   Ephedrine   epicatechin   epigallocatechin   estradiol   estragole   Estrone-2,3-quinone   etanercept   ethoxzolamide   ethyl lauroyl arginine hydrochloride   Euchrenone   eugenol   Evusheld   EXO-CD24   ezetimibe   famotodine   Fangchinoline   Farnesiferol B   fenofibrate   Ferrocene derivatives   Ferulic acid   fingolimod   flecainide   FLOVID-20   fluoxetine   Forsythoside A   Forsythoside I   Fostamatinib   fucoidan   Galangin   galidesivir   Gallic acid   ganciclovir   Genistein   gimsilumab   Glabridin   glutathione   glycyrrhiza glabra L.   Green Tea   Griffithsin   heparin   Hesperidin   honey   Huashibaidu   hydrogen peroxide   hydroxyzine   Hypericin   ibrutinib   ibuprofen   IFN-β1a   IFN-β1b   IFX-1   imatinib   immunoglobulin   indinavir   Indomethacin   infliximab   interleukin-2   Irisolidone   Isatis indigotica root   Isoferulic acid   Isorhamnetin   jakotinib hydrochloride   Jing Si   Jinhua Qinggan   JS016   Kabasura Kudineer   Kaempferol   Kobophenol A   L-arginine   L-Lysine   lactoferrin   leflunomide   lenzilumab   leronlimab   levilimab   Lianhua Qingwen   Limonene   Limonin   lopinavir   loratadine   losartan   Lung Cleansing and Detoxifying Decoction   Luteolin   LY2835219   LY3127804   manidipine   Manuka honey   masitinib   Maslinic acid   Mearnsitrin   meplazumab   MesenCure   methylene blue   Methylephedrine   MUC1   multimeric soluble ACE2   myricetin   Myricitrin   N-Acetylcysteine   N-acetylglucosamine   nafamostat   naproxen   Naringenin   natto extract   neem   negillicine   nelfinavir   Neochlorogenic acid   niacinamide   niclosamide   nicotinamide mononucleotide   nicotine   nitric oxide   nivolumab   Obacunone   obtivo   Oleuropein   Omega 3   Oroxylin A   oxygen-ozone immunoceutical therapy   p-coumaroyltriacetic acid lactone   palmitoylated ACE2   panobinostat   paritaprevir   paroxetine   pegylated interferon alfa-2b   pentosan polysulfate   Phillyrin   phosphodiesterase enzyme type 5 inhibitors   phthalocyanine   piclidenoson   piperaquine   pirfenidone   Poly-hydroxyflavones   Poly-methoxyflavones   Pomegranate   probenecid   Procyanidin   propolis   propolis sulabiroin-A   Pseudoephedrine   Psoralidin   Pterostilbene   Puerarin   Pyramax   pyronaridine   Q34   Quercetin 3-O-rutinoside   raltegravir   ramelteon   ramipril   ravulizumab   RD-X19   regdanvimab   resveratrol   Rhein   Rheum palmatum   Rhizoma Cibotii   ribavirin   ritonavir   rosuvastatin   rutin   ruxolitinib   saline   Salvianolic acid   saquinavir   Scutellarein   sea cucumber sulfated polysaccharide   selamectin   selenium   sertraline   Sesamin   Sesaminol   Sesamolin   Shuang Huang Lian   silibinin   Silmitasertib   SN00074072   sodium bicarbonate   sofosbuvir   Solanine   Speciophylline   spironolactone   Spirulina   stenoparib   suramin sodium   tannic acid   Tanshinones   Taraxerol   telmisartan   tenofovir alafenamide   tenofovir disoproxil   Tetrandrine   theaflavin-3,3’-digallate   thiamine   thymic peptides   TJ003234   tocilizumab   tofacitinib   Tollovir   toremifene   Torreya nucifera   tozumab   TriSb92   ubiquinone   Uncaric acid   Uncarine F   Urso-deoxycholic acid   Ursolic acid   valsartan   Withanolide A   Xanthoangelol E   Xuanfeibaidu   Xuebijing   xylitol   ZINC02111387   ZINC02122196   ZINC04090608   α-hederin   α-lactalbumin   β-glucan   β-sitosterol   δ-viniferin  
https://www.mdpi.com/2304-8158/10/9/2084/htm
Serra et al., Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation, Briefings in Bioinformatics, doi:10.1093/bib/bbab507
https://www.biorxiv.org/content/10.1101/2021.06.04.447066v2
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Li et al., Inpatient Use of Metformin and Acarbose Is Associated with Reduced Mortality of COVID-19 Patients with Type 2 Diabetes Mellitus, Research Square, doi:10.21203/rs.3.rs-287308/v1
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Mahoney et al., Antiviral Activity of Aframomum melegueta Against Severe Acute Respiratory Syndrome Coronaviruses type 1 and 2, South African Journal of Botany, doi:10.1016/j.sajb.2021.12.010
https://www.mdpi.com/2304-8158/10/9/2084/htm
Cecon et al., Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels, bioRxiv, doi:10.1101/2021.12.30.474561
https://www.nature.com/articles/s42003-021-02866-9
https://www.nature.com/articles/s41594-020-00536-8
https://www.researchsquare.com/article/rs-121743/v1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063946/
https://www.nature.com/articles/s41392-021-00558-8
https://pubmed.ncbi.nlm.nih.gov/33344913/
https://www.sciencedirect.com/science/article/pii/S092485792030162X
https://www.eurekaselect.com/183729/article
https://link.springer.com/article/10.1007/s43440-021-00231-5
https://link.springer.com/article/10.1007/s40268-021-00351-6
https://www.researchsquare.com/article/rs-493154/v1
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.mdpi.com/1424-8247/14/3/226
https://www.cell.com/cell-reports-medicine/pdf/S2666-3791(20)30186-5.pdf
https://www.mdpi.com/1424-8247/14/3/226
https://www.mdpi.com/1424-8247/14/3/226
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.pnas.org/content/118/1/e2021450118 (In Vitro)
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://pubs.asahq.org/anesthesiology/article-abstract/doi/10.1097/ALN.0000000000003999/11..
https://www.biorxiv.org/content/10.1101/2021.09.10.459744v1.full.pdf (In Vitro)
https://clinicaltrials.gov/ct2/show/NCT04335136
https://www.sciencedirect.com/science/article/abs/pii/S0040595721002043
https://www.sciencedirect.com/science/article/pii/S0953620521003071
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Li et al., Hypertonic saline and aprotinin based blockage of SARS-CoV-2 specific furin site cleavage by inhibition of nasal protease activity, bioRxiv, doi:10.1101/2021.11.19.469276
https://onlinelibrary.wiley.com/doi/full/10.1002/iid3.502
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-020-05698-w
https://www.mdpi.com/1999-4915/13/8/1665
https://www.newindianexpress.com/nation/2021/sep/15/clinical-trial-of-anti-viral-drug-umif..
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
https://www.pnas.org/content/118/1/e2021450118 (In Vitro)
https://www.degruyter.com/document/doi/10.1515/jcim-2021-0241/html (In Silico)
https://www.sciencedirect.com/science/article/abs/pii/S0378874121002439
https://chemrxiv.org/engage/chemrxiv/article-details/60c74a53469df45440f43d21
https://www.openaccessjournals.com/articles/targeting-tgf-pathway-with-covid19-drug-candid..
https://www.biorxiv.org/content/10.1101/2021.09.08.459260v1 (In Vitro)
https://www.biorxiv.org/content/10.1101/2020.04.13.039917v3 (In Vitro)
https://linkinghub.elsevier.com/retrieve/pii/S0378874121002439
https://pubmed.ncbi.nlm.nih.gov/34306988/
https://clinicaltrials.gov/ct2/show/NCT04530617
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0965229921001096
https://osf.io/s3v6k/
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Chaves et al., Atazanavir is a competitive inhibitor of SARS-CoV-2 Mpro, impairing variants replication in vitro and in vivo, bioRxiv, doi:10.1101/2021.11.24.469775
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
https://www.sciencedirect.com/science/article/pii/S2352906721001639
https://onlinelibrary.wiley.com/doi/10.1111/ijcp.14434 (Retrospective Study)
https://www.mdpi.com/1999-4915/13/10/2084
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
https://pubs.acs.org/doi/abs/10.1021/acsinfecdis.1c00278 (In Vitro)
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.astrazeneca.com/media-centre/press-releases/2021/azd7442-prophylaxis-trial-met..
https://trialsitenews.com/astrazeneca-files-request-for-emergency-use-authorization-for-lo..
https://www.biorxiv.org/content/10.1101/2020.09.15.296228v1
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144927/
https://pubmed.ncbi.nlm.nih.gov/34052578/
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)
https://www.researchsquare.com/article/rs-864566/v1
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Serra et al., Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation, Briefings in Bioinformatics, doi:10.1093/bib/bbab507
https://www.mdpi.com/1424-8247/14/9/892
https://www.karger.com/Article/Abstract/519564
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/abs/pii/S2213260021003313
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Al Khoury et al., In silico evidence of beauvericin antiviral activity against SARS-CoV-2, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.105171
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253489
https://trialsitenews.com/brii-bio-initiates-submission-of-emergency-use-authorization-fil..
https://www.sciencedirect.com/science/article/pii/S2589936820300463?via%3Dihub
https://www.nature.com/articles/s41598-021-97268-6
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.biorxiv.org/content/10.1101/2021.08.05.455262v1
https://arxiv.org/abs/2108.13764ANIMAL:https://journals.asm.org/doi/full/10.1128/mBio.0097.. (In Silico)
https://www.sciencedirect.com/science/article/pii/S2352396421000487 (In Vitro)
https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(21)00048-7/fulltext
https://www.europeanpharmaceuticalreview.com/news/159375/camostat-cuts-recovery-time-in-ha..
https://clinicaltrials.gov/ct2/show/NCT04530617
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.biorxiv.org/content/10.1101/2021.03.10.432967v1
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286244/pdf/main.pdf
https://www.mdpi.com/1424-8247/14/3/226
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)
https://www.nature.com/articles/s41392-021-00689-y (Retrospective Study)
https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)
https://www.biorxiv.org/content/10.1101/2020.10.28.359257v1 (In Vitro)
https://www.sciencedirect.com/science/article/pii/S0929664621004691 (Review)
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Huang et al., Use of chlorhexidine to eradicate oropharyngeal SARS‐CoV‐2 in COVID‐19 patients, Journal of Medical Virology, doi:10.1002/jmv.26954
https://www.sciencedirect.com/science/article/pii/S0929664621004691 (Review)
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8291116/
https://www.medrxiv.org/content/10.1101/2021.09.07.21261811v1
Clemency et al., Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19, JAMA Internal Medicine, doi:10.1001/jamainternmed.2021.6759
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Song et al., Oral antiviral clevudine compared with placebo in Korean COVID-19 patients with moderate severity, medRxiv, doi:10.1101/2021.12.09.21267566
Belouzard et al., Clofoctol inhibits SARS-CoV-2 replication and reduces lung pathology in mice, bioRxiv, doi:10.1101/2021.06.30.450483
You et al., Structural characterization and SARS-CoV-2 inhibitory activity of a sulfated polysaccharide from Caulerpa lentillifera, Carbohydrate Polymers, doi:10.1016/j.carbpol.2021.119006
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.jpost.com/health-and-wellness/israeli-scientists-say-their-antiviral-drug-coul..
https://www.biorxiv.org/content/10.1101/2021.09.17.460613v1
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.clinicaltherapeutics.com/article/S0149-2918(21)00308-8/fulltext
https://www.sciencedirect.com/science/article/pii/S0006291X21009311
https://www.sciencedirect.com/science/article/pii/S0006291X21013176
https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(21)005..
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.biorxiv.org/content/10.1101/2021.10.02.462862v1
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.pnas.org/content/118/1/e2021450118 (In Vitro)
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.sciencedirect.com/science/article/pii/S2772417421000133
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://con.antppublishing.com/index.php/ittpcovid19/article/view/183
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889471/ (In Vitro)
https://www.mdpi.com/1424-8247/14/3/226
https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)
https://academic.oup.com/qjmed/advance-article/doi/10.1093/qjmed/hcab184/6329274
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://pubmed.ncbi.nlm.nih.gov/32473509/
Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)
Ostrov et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, Pathogens, doi:10.3390/pathogens10111514
https://www.biorxiv.org/content/10.1101/2021.09.17.460613v1
https://www.sciencedirect.com/science/article/pii/S1319562X21007968
https://con.antppublishing.com/index.php/ittpcovid19/article/view/183
https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1
Rose et al., The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality From COVID-19, Frontiers in Medicine, doi:10.3389/fmed.2021.637647
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0308814621026005
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S2213422021000688
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Ikemura et al., Engineered ACE2 counteracts vaccine-evading SARS-CoV-2 Omicron variant, bioRxiv, doi:10.1101/2021.12.22.473804
https://pubs.asahq.org/anesthesiology/article-abstract/doi/10.1097/ALN.0000000000003999/11..
https://www.pnas.org/content/118/1/e2021450118ANIMAL:https://www.nature.com/articles/s4146.. (In Vitro)
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Al-Shuhaib et al., Epicatechin is a promising novel inhibitor of SARS-CoV-2 entry by disrupting interactions between angiotensin-converting enzyme type 2 and the viral receptor binding domain: A computational/simulation study, Computers in Biology and Medicine, doi:10.1016/j.compbiomed.2021.105155
Park et al., Epigallocatechin Gallate (EGCG), a Green Tea Polyphenol, Reduces Coronavirus Replication in a Mouse Model, Viruses, doi:10.3390/v13122533
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/1424-8247/14/9/892
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0308814621026005
https://journals.physiology.org/doi/full/10.1152/ajplung.00153.2020
https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1
https://physoc.onlinelibrary.wiley.com/doi/full/10.14814/phy2.14707
https://www.mdpi.com/1424-8247/14/9/892
Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
https://www.biorxiv.org/content/10.1101/2021.09.25.461785v1
https://www.researchsquare.com/article/rs-842564/v1 (In Vitro)
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/1424-8247/14/9/892
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-author..
https://www.jpost.com/health-science/covid-90-percent-of-patients-treated-with-new-israeli..
https://elifesciences.org/articles/68165
https://www.frontiersin.org/articles/10.3389/fphar.2021.633680/full
https://pubmed.ncbi.nlm.nih.gov/33625612/
https://pubmed.ncbi.nlm.nih.gov/32852338/
https://www.researchsquare.com/article/rs-369927/v1
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3646583
https://www.researchsquare.com/article/rs-526394/v1
Mura et al., Real-world evidence for improved outcomes with histamine antagonists and aspirin in 22,560 COVID-19 patients, Signal Transduction and Targeted Therapy, doi:10.1038/s41392-021-00689-y
https://pubmed.ncbi.nlm.nih.gov/33757133/
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.researchsquare.com/article/rs-770724/v1
https://www.frontiersin.org/articles/10.3389/fphar.2021.660490/full
https://www.sciencedirect.com/science/article/pii/S2049080121009249
Abbas et al., Synthesis and investigation of anti-COVID19 ability of ferrocene Schiff base derivatives by quantum chemical and molecular docking, Journal of Molecular Structure, doi:10.1016/j.molstruc.2021.132242
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://elifesciences.org/articles/68165
https://flowpharma.com/product/flovid-20/
https://www.tandfonline.com/doi/full/10.1080/22221751.2020.1829082
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3896539
https://www.nature.com/articles/s41598-021-85049-0
https://pubmed.ncbi.nlm.nih.gov/32975484/
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/abs/pii/S104620232100205X (In Silico)
https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo02017f/unauth
https://www.sciencedirect.com/science/article/pii/S2589014X20302450https://www.mdpi.com/16..
https://www.sciencedirect.com/science/article/abs/pii/S0144861721009541
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://pubmed.ncbi.nlm.nih.gov/32463221/
https://pubmed.ncbi.nlm.nih.gov/32992775/
https://pubmed.ncbi.nlm.nih.gov/32708578/
https://pubmed.ncbi.nlm.nih.gov/33336769/
https://pubmed.ncbi.nlm.nih.gov/33117175/
https://pubmed.ncbi.nlm.nih.gov/32322478/
Bisht et al., Revisiting liquorice (Glycyrrhiza glabra L.) as anti-inflammatory, antivirals and immunomodulators: potential pharmacological applications with mechanistic insight., Phytomedicine Plus, doi:10.1016/j.phyplu.2021.100206
https://www.mdpi.com/1999-4915/13/4/609/pdf
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8227143/
https://pubmed.ncbi.nlm.nih.gov/33918301/
https://www.sciencedirect.com/science/article/pii/S2667031321000257
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-020-04706-3
https://www.frontiersin.org/articles/10.3389/fphar.2021.631206/full
https://www.mdpi.com/2223-7747/10/12/2600
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://pubmed.ncbi.nlm.nih.gov/34375189/ (In Vitro)
https://www.mdpi.com/1660-3397/19/8/418
https://www.sciencedirect.com/science/article/abs/pii/S1386142521011720
https://www.mdpi.com/2072-6643/13/8/2800
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.medrxiv.org/content/10.1101/2020.10.30.20217364v4
https://www.sciencedirect.com/science/article/abs/pii/S0944711321004086
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7308628/REVIEW:https://www.sciencedirect.com/..
http://www.orthomolecular.org/resources/omns/v17n13.shtml
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)
https://www.mdpi.com/2304-8158/10/9/2084/htm
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.medrxiv.org/content/10.1101/2021.07.24.21261007v2 (RCT)
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Lu et al., Jing Si Herbal Drink as a Prospective Adjunctive Therapy for COVID-19 Treatment: Molecular evidence and mechanisms, Pharmacological Research - Modern Chinese Medicine, doi:10.1016/j.prmcm.2021.100024
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
https://trialsitenews.com/chinese-monoclonal-antibody-product-sees-expansion-in-use-worldw..
https://pubmed.ncbi.nlm.nih.gov/34526104/ (RCT)
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(21)00405-3/fulltext (RCT)
https://www.mdpi.com/1999-4915/13/7/1301/htm
https://www.researchgate.net/publication/354035681_Theoretical_Discussion_of_the_Probable_..
https://www.researchgate.net/publication/345916326_Amino_Acid_L-Lysine_SARS-CoV-2_COVID-19..
https://www.researchgate.net/publication/344210822_Lysine_Therapy_for_SARS-CoV-2
https://www.pnas.org/content/118/36/e2105815118
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC8469309/
https://ijrhs.org/sites/default/files/IntJResHealthSci-8-1-8.pdf
https://medicalxpress.com/news/2021-08-drugs-sars-cov2-cells.html
https://www.biorxiv.org/content/10.1101/2020.08.11.244996v4
https://ijponline.biomedcentral.com/articles/10.1186/s13052-021-00990-0
https://www.frontiersin.org/articles/10.3389/fimmu.2020.01221/full
https://www.mdpi.com/2076-0817/10/11/1514/htm
Ostrov et al., Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells, Pathogens, doi:10.3390/pathogens10111514
Wang et al., Lactoferrin for the treatment of COVID‑19 (Review), Experimental and Therapeutic Medicine, doi:10.3892/etm.2020.9402
Zimecki et al., The potential for Lactoferrin to reduce SARS-CoV-2 induced cytokine storm, International Immunopharmacology, doi:10.1016/j.intimp.2021.107571
van der Strate et al., Antiviral activities of lactoferrin, Antiviral Research, doi:10.1016/S0166-3542(01)00195-4
Wakabayashi et al., Lactoferrin for prevention of common viral infections, Journal of Infection and Chemotherapy, doi:10.1016/j.jiac.2014.08.003
Mattar et al., Natural resources to control COVID-19: could lactoferrin amend SARS-CoV-2 infectivity?, PeerJ, doi:10.7717/peerj.11303
Campione et al., Lactoferrin Against SARS-CoV-2: In Vitro and In Silico Evidences, Frontiers in Pharmacology, doi:10.3389/fphar.2021.666600
Salaris et al., Protective Effects of Lactoferrin against SARS-CoV-2 Infection In Vitro, Nutrients, doi:10.3390/nu13020328
Algahtani et al., The Prospect of Lactoferrin Use as Adjunctive Agent in Management of SARS-CoV-2 Patients: A Randomized Pilot Study, Medicina, doi:10.3390/medicina57080842
https://www.biorxiv.org/content/10.1101/2021.10.29.466402v1
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00494-X/fulltext
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://link.springer.com/article/10.1007/s00011-021-01507-5 (RCT)
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7889471/ (In Vitro)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7713548/ (Retrospective Study)
https://www.sciencedirect.com/science/article/abs/pii/S1094553921000018 (Retrospective Study)
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
https://pubmed.ncbi.nlm.nih.gov/34236507/ (In Silico)
Munafò et al., Quercetin and Luteolin Are Single-digit Micromolar Inhibitors of the SARS-CoV-2 RNA-dependent RNA Polymerase, Research Square, doi:10.21203/rs.3.rs-1149846/v1
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
https://qspace.qu.edu.qa/handle/10576/24398
Drayman et al., Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2, Science, doi:10.1126/science.abg5827
Martínez‐Ortega et al., In Silico Characterization of Masitinib Interaction with SARS‐CoV‐2 Main Protease, ChemMedChem, doi:10.1002/cmdc.202100375
Drayman et al., Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro, bioRxiv, doi:10.1101/2020.08.31.274639
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.jpost.com/health-and-wellness/coronavirus/israeli-drug-for-severe-covid-reduce..
https://www.frontiersin.org/articles/10.3389/fphar.2020.600372/full
https://www.sciencedirect.com/science/article/pii/S0753332221008064
https://pubmed.ncbi.nlm.nih.gov/34019535/
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.biorxiv.org/content/10.1101/2021.10.29.466402v1
Kayabolen et al., Protein scaffold-based multimerization of soluble ACE2 efficiently blocks SARS-CoV-2 infection in vitro and in vivo, bioRxiv, doi:10.1101/2021.01.04.425128
https://www.mdpi.com/1424-8247/14/9/892
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://jmscr.igmpublication.org/home/index.php/current-issue/10082-inhalation-of-vapor-wi..
https://www.dovepress.com/n-acetylcysteine-to-combat-covid-19-an-evidence-review-peer-revi..
https://chemrxiv.org/engage/chemrxiv/article-details/60c753ec4c89190f3bad43ca
https://www.dovepress.com/n-acetylcysteine-as-adjuvant-therapy-for-covid-19--a-perspective..
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649937/
https://clinicaltrials.gov/ct2/show/NCT04419025
https://trialsjournal.biomedcentral.com/articles/10.1186/s13063-021-05242-4
https://www.cebm.net/covid-19/n-acetylcysteine-a-rapid-review-of-the-evidence-for-effectiv..
https://www.cancer.gov/about-cancer/treatment/clinical-trials/search/v?id=NCI-2020-03373
https://www.futuremedicine.com/doi/10.2217/fmb-2020-0074
https://www.liebertpub.com/doi/10.1089/ars.2020.8247
https://clinicaltrials.gov/ct2/show/NCT04419025
https://f1000research.com/articles/9-491
https://pubmed.ncbi.nlm.nih.gov/34262324/
https://pubmed.ncbi.nlm.nih.gov/33371832/
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7649937/
https://www.wjgnet.com/2220-3249/full/v10/i2/34.htm
https://www.researchgate.net/publication/346505588_N-acetylcysteine_to_combat_COVID-19_An_..
https://chemrxiv.org/engage/chemrxiv/article-details/60c753ec4c89190f3bad43ca
https://sites.kowsarpub.com/iji/articles/106361.html
https://www.europeanreview.org/article/25442
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0248132
https://journals.lww.com/md-journal/fulltext/2020/10160/experience_of_n_acetylcysteine_air..
https://www.sciencedirect.com/science/article/pii/S2049080121005240
https://www.mdpi.com/1999-4915/13/9/1768 (In Vitro)
https://journals.asm.org/doi/full/10.1128/mBio.00970-21 (Animal Study)
https://www.biorxiv.org/content/10.1101/2021.07.08.451654v1 (Animal Study)
https://www.sciencedirect.com/science/article/pii/S2589537021004491 (RCT)
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.mdpi.com/1420-3049/26/9/2593/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0006291X21010718
https://pubmed.ncbi.nlm.nih.gov/33891569/ (RCT)
https://www.sciencedirect.com/science/article/pii/S1319562X21007968
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://kidney360.asnjournals.org/content/2/1/33?WT.MC_ID=TMD01&utm_campaign=Kidney360_Tre..
https://www.sciencedirect.com/science/article/pii/S2049080121007299
https://www.egaceutical.com/wp-content/uploads/2021/12/rapid-clinical-improvement-in-ill-c..
https://pubmed.ncbi.nlm.nih.gov/32790936/
https://clinicaltrials.gov/ct2/show/NCT04583410
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8117664/pdf/main.pdfhttps://pubmed.ncbi.nlm.n..
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/abs/pii/S0952327821000132
https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-021-02795-5
https://www.authorea.com/doi/full/10.22541/au.161051252.26168891
https://www.sciencedirect.com/science/article/pii/S2589004221010087
https://www.plefa.com/article/S0952-3278(21)00013-2/fulltext
https://www.nature.com/articles/s41598-021-91794-z
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Franzini et al., Oxygen-ozone (O2-O3) immunoceutical therapy for patients with COVID-19. Preliminary evidence reported, International Immunopharmacology, doi:10.1016/j.intimp.2020.106879
Bhowmick et al., Identification of potent food constituents as SARS-CoV-2 papain-like protease modulators through advanced pharmacoinformatics approaches, Journal of Molecular Graphics and Modelling, doi:10.1016/j.jmgm.2021.108113
https://onlinelibrary.wiley.com/doi/full/10.1002/adma.202103471
https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1009840
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7286244/pdf/main.pdf
https://www.sciencedirect.com/science/article/pii/S1201971221006779 (RCT)
Bertini et al., Pentosan polysulfate inhibits attachment and infection by SARS-CoV-2 in vitro: insights into structural requirements for binding., bioRxiv, doi:10.1101/2021.12.19.473359
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC7883493/
https://pubmed.ncbi.nlm.nih.gov/32526061/
https://www.nature.com/articles/s41598-021-99013-5 (RCT)
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Artigas et al., In-silico drug repurposing study predicts the combination of pirfenidone and melatonin as a promising candidate therapy to reduce SARS-CoV-2 infection progression and respiratory distress caused by cytokine storm, PLOS ONE, doi:10.1371/journal.pone.0240149
https://www.sciencedirect.com/science/article/pii/S2590257121000523 (In Silico)
https://www.sciencedirect.com/science/article/pii/S2590257121000523 (In Silico)
https://link.springer.com/article/10.1007/s11010-020-03981-7
https://psmpublishers.org/issues/the-use-of-fresh-pomegranate-juice-in-the-treatment-of-co..
https://www.sciencedirect.com/science/article/pii/S0045206821005228
https://www.nature.com/articles/s41598-021-97658-w (Animal Study)
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0753332221003115 (RCT)
https://www.medrxiv.org/content/10.1101/2021.01.08.20248932v1
https://www.scienceopen.com/hosted-document?doi=10.14293/S2199-1006.1.SOR-.PPZR1OD.v1
https://www.sciencedirect.com/science/article/pii/S1018364721003694
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.koreabiomed.com/news/articleView.html?idxno=11556
https://www.biorxiv.org/content/10.1101/2021.09.30.462449v1
Cui et al., Compound screen identifies the small molecule Q34 as an inhibitor of SARS-CoV-2 infection, iScience, doi:10.1016/j.isci.2021.103684
https://www.mdpi.com/2304-8158/10/9/2084/htm
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Cecon et al., Melatonin drugs inhibit SARS-CoV-2 entry into the brain and virus-induced damage of cerebral small vessels, bioRxiv, doi:10.1101/2021.12.30.474561
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.medrxiv.org/content/10.1101/2021.10.17.21265058v1
https://pubmed.ncbi.nlm.nih.gov/34724174/
https://www.medrxiv.org/content/10.1101/2020.07.21.20151423v1 (Retrospective Study)
https://www.mdpi.com/2076-3921/10/9/1440
https://www.tandfonline.com/doi/full/10.1080/21623945.2021.1965315
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S0308814621026005
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.sciencedirect.com/science/article/pii/S2213422021000688
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Gaitán-Duarte et al., Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19, medRxiv, doi:10.1101/2021.07.06.21260085
https://elifesciences.org/articles/68165
Srus et al., In Silico study of Wheatgrass constituents against Coronavirus COVID-19 Proteins., Research Square, doi:10.21203/rs.3.rs-1167417/v1
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/1424-8247/14/9/892
https://www.mdpi.com/2304-8158/10/9/2084/htm
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
https://pubmed.ncbi.nlm.nih.gov/33772626/ (Review)
Li et al., Hypertonic saline and aprotinin based blockage of SARS-CoV-2 specific furin site cleavage by inhibition of nasal protease activity, bioRxiv, doi:10.1101/2021.11.19.469276
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://pubs.rsc.org/en/content/articlelanding/2020/fo/d0fo02017f/unauth
https://www.biorxiv.org/content/10.1101/2021.04.08.439071v1
https://pubmed.ncbi.nlm.nih.gov/32992282
https://www.sciencedirect.com/science/article/pii/S030698772031104X
https://www.sciencedirect.com/science/article/pii/S2405457721011074
https://www.mdpi.com/2072-6643/11/9/2101
https://www.mdpi.com/1424-8247/14/3/226
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S2213422021000688
Bosch-Barrera et al., Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients, Journal of Clinical Medicine, doi:10.3390/jcm9061770
https://www.senhwabio.com/en/news/20211020
https://trialsitenews.com/senhwa-presents-positive-data-from-phase-2-trial-of-silmitaserti..
Power et al., Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein, Bioorganic Chemistry, doi:10.1016/j.bioorg.2021.105574
https://oaltoacre.com/pesquisa-do-acre-tem-resultado-positivo-no-uso-do-bicarbonato-contra..
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://pubmed.ncbi.nlm.nih.gov/34375189/ (In Vitro)
https://www.biorxiv.org/content/10.1101/2021.11.03.467186v1
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://pubmed.ncbi.nlm.nih.gov/33415017/
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
Frediansyah et al., Antivirals for COVID-19: A critical review, Clinical Epidemiology and Global Health, doi:10.1016/j.cegh.2020.07.006
https://www.sciencedirect.com/science/article/pii/S2213422021000688
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0253489
https://ccforum.biomedcentral.com/articles/10.1186/s13054-021-03648-9 (Retrospective Study)
Ramos-Zaldívar et al., A nonrandomized phase 2 trial of oral thymic peptides in hospitalized patients with Covid-19, medRxiv, doi:10.1101/2021.12.05.21267318
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
Heimfarth et al., Drug repurposing and cytokine management in response to COVID-19: A review, International Immunopharmacology, doi:10.1016/j.intimp.2020.106947
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://trialsitenews.com/todos-medicals-antiviral-treatment-tollovir-reduces-covid-19-mor..
https://www.biorxiv.org/content/10.1101/2020.04.13.039917v3
https://www.sciencedirect.com/science/article/pii/S2213422021000688
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.biorxiv.org/content/10.1101/2021.12.28.474326v1
https://elifesciences.org/articles/68165
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Sarkar et al., Potential Therapeutic Options for COVID-19: Current Status, Challenges, and Future Perspectives, Frontiers in Pharmacology, doi:10.3389/fphar.2020.572870
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.mdpi.com/2304-8158/10/9/2084/htm
https://www.sciencedirect.com/science/article/pii/S2095809921004422
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
Wu et al., Prospective: Evolution of Chinese Medicine to Treat COVID-19 Patients in China, Frontiers in Pharmacology, doi:10.3389/fphar.2020.615287
https://www.cureus.com/articles/43909-potential-role-of-xylitol-plus-grapefruit-seed-extra..
https://probiologists.com/Uploads/Articles/11_637497463703161509.pdf
https://www.biorxiv.org/content/10.1101/2020.12.02.408575v3.full.pdf
https://www.researchgate.net/publication/347176706_A_Nasal_Spray_Solution_of_Grapefruit_Se..
https://www.precisionvaccinations.com/nasal-spray-may-eliminate-sars-cov-2-virus
Power et al., Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein, Bioorganic Chemistry, doi:10.1016/j.bioorg.2021.105574
Power et al., Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein, Bioorganic Chemistry, doi:10.1016/j.bioorg.2021.105574
Power et al., Virtual screening and in vitro validation of natural compound inhibitors against SARS-CoV-2 spike protein, Bioorganic Chemistry, doi:10.1016/j.bioorg.2021.105574
https://www.sciencedirect.com/science/article/pii/S1319562X21007968
https://www.biorxiv.org/content/10.1101/2021.10.29.466402v1
Banitalebi et al., In silico study of potential immunonutrient-based sports supplements against COVID-19 via targeting ACE2 inhibition using molecular docking and molecular dynamics simulations, Journal of Biomolecular Structure and Dynamics, doi:10.1080/07391102.2021.2016489
https://www.sciencedirect.com/science/article/pii/S0223523421007066
https://www.sciencedirect.com/science/article/pii/S0223523421007066
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All practical, effective, and safe means should be used. Elimination of COVID-19 is a race against viral evolution. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases the risk of COVID-19 becoming endemic; and increases mortality, morbidity, and collateral damage. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. Treatment protocols for physicians are available from the FLCCC.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit    
Share
Tweet
@CovidAnalysis
FAQ
Public domain CC0 1.0